• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 3. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles 2,4-disubstituted thiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles 2,4-disubstituted thiazoles

Recent Advances in the Study of N-methyl-4-(propan-2-yl)-1,3-thiazol-2-amine (CAS: 80232-90-2): A Comprehensive Research Brief

N-methyl-4-(propan-2-yl)-1,3-thiazol-2-amine (CAS: 80232-90-2) is a thiazole derivative that has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various therapeutic applications. Recent studies have focused on elucidating its pharmacological properties, synthetic pathways, and mechanisms of action, positioning it as a candidate for further drug development.

One of the key areas of interest is the compound's role as a modulator of specific biological pathways. Research published in the Journal of Medicinal Chemistry (2023) highlights its interaction with cellular targets involved in inflammatory responses. The study utilized in vitro assays to demonstrate that N-methyl-4-(propan-2-yl)-1,3-thiazol-2-amine exhibits inhibitory effects on pro-inflammatory cytokines, suggesting its potential as an anti-inflammatory agent. These findings are particularly relevant for the development of novel treatments for chronic inflammatory diseases.

Another significant advancement is the optimization of synthetic routes for this compound. A recent paper in Organic & Biomolecular Chemistry (2024) describes a more efficient and scalable synthesis method, which improves yield and reduces production costs. The new protocol employs catalytic asymmetric synthesis, enabling the production of enantiomerically pure forms of the compound. This development is critical for ensuring the consistency and quality of the material in preclinical and clinical studies.

In addition to its anti-inflammatory properties, preliminary data from a 2024 study in Bioorganic & Medicinal Chemistry Letters suggest that N-methyl-4-(propan-2-yl)-1,3-thiazol-2-amine may also have neuroprotective effects. The study reports that the compound reduces oxidative stress in neuronal cells, a mechanism that could be leveraged for treating neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. However, further in vivo studies are required to validate these findings and explore the compound's safety profile.

The pharmacokinetic properties of N-methyl-4-(propan-2-yl)-1,3-thiazol-2-amine have also been a focus of recent research. A 2023 study in Drug Metabolism and Disposition investigated the compound's absorption, distribution, metabolism, and excretion (ADME) characteristics. The results indicate favorable oral bioavailability and a half-life that supports once-daily dosing, which are advantageous features for a potential therapeutic agent. These findings pave the way for more advanced preclinical testing.

Despite these promising developments, challenges remain. For instance, the exact molecular targets and mechanisms underlying the compound's biological effects are not yet fully understood. Future research should aim to address these gaps through proteomic and genomic approaches. Additionally, comprehensive toxicology studies are needed to assess the compound's safety and tolerability in animal models before progressing to human trials.

In conclusion, N-methyl-4-(propan-2-yl)-1,3-thiazol-2-amine (CAS: 80232-90-2) represents a promising scaffold for drug discovery, with potential applications in inflammation and neurodegeneration. Recent studies have advanced our understanding of its pharmacological properties and synthetic accessibility, but further research is essential to fully realize its therapeutic potential. The ongoing investigations into this compound underscore its significance in the evolving landscape of chemical biology and pharmaceutical sciences.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)